OCM
IMRX icon

Occam Crest Management’s Immuneering IMRX Stock Holding History

Occam Crest Management’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.87M Buy
545,098
+46,600
+9% +$239K 1.74% 20
2025
Q4 		$3.28M Hold
498,498
– – 2.28% 15
2025
Q3 		$3.49M Buy
+498,498
New +$2.59M 2.12% 15

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Occam Crest Management's IMRX Position: Q1 2026 in Review

Occam Crest Management increased its Immuneering (IMRX) stake by 9.3% in Q1 2026, buying an estimated $239K and bringing the position to 545,098 shares worth $2.87M. The position accounts for 1.74% of the portfolio, ranked #20.

Occam Crest Management first reported a position in IMRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $3.49M in Q3 2025. 95 funds tracked by Wall St. Rank hold IMRX as of Q1 2026.

  • Occam Crest Management held 545,098 shares of Immuneering worth $2.87M as of Q1 2026.
  • Occam Crest Management bought 46,600 Immuneering shares in Q1 2026, an estimated $239K.
  • Immuneering made up 1.74% of Occam Crest Management's portfolio in Q1 2026, its #20 holding.
  • Occam Crest Management first reported a position in Immuneering in Q3 2025 and has held it in 3 quarters since.
  • Occam Crest Management's Immuneering position peaked at $3.49M in Q3 2025.
  • 95 funds tracked by Wall St. Rank held Immuneering as of Q1 2026.

Based on Occam Crest Management's 13F filing for Q1 2026, filed 15 May 2026.